Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells

The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, is used widely to treat non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Unfortunately, the acquired drug resistance promoted by epithelial-mesenchymal transition (EMT) markedly limits the clinica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Rep
Hlavní autoři: Li, Fangqiong, Cui, Huaizhong, Jin, Xin, Gong, Xiaoting, Wang, Wei, Wang, Juan
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2020
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107945/
https://ncbi.nlm.nih.gov/pubmed/32323848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2020.7542
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky